4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of “Moderate Buy” by Brokerages

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been assigned an average rating of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $29.8750.

FDMT has been the topic of several research reports. Jefferies Financial Group restated a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday, March 30th. Royal Bank Of Canada increased their target price on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, March 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Monday, April 20th. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, March 20th. Finally, Chardan Capital restated a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th.

4D Molecular Therapeutics Stock Performance

Shares of 4D Molecular Therapeutics stock opened at $13.00 on Friday. 4D Molecular Therapeutics has a 1 year low of $3.86 and a 1 year high of $14.00. The company’s fifty day simple moving average is $9.87 and its 200-day simple moving average is $9.23. The company has a market cap of $679.64 million, a price-to-earnings ratio of -5.06 and a beta of 2.70.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The company had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. As a group, research analysts forecast that 4D Molecular Therapeutics will post -4.14 earnings per share for the current fiscal year.

Insider Activity at 4D Molecular Therapeutics

In other news, insider David Kirn sold 114,746 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the sale, the insider directly owned 942,485 shares in the company, valued at approximately $9,867,817.95. The trade was a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Scott Bizily sold 9,810 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the transaction, the insider owned 8,617 shares of the company’s stock, valued at $103,404. The trade was a 53.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 126,478 shares of company stock worth $1,338,369 in the last three months. 7.90% of the stock is owned by insiders.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently bought and sold shares of FDMT. Dynamic Technology Lab Private Ltd bought a new stake in 4D Molecular Therapeutics in the 1st quarter valued at $39,000. Wexford Capital LP bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter worth about $41,000. AQR Capital Management LLC acquired a new stake in shares of 4D Molecular Therapeutics during the 1st quarter valued at about $46,000. Daiwa Securities Group Inc. boosted its position in shares of 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after acquiring an additional 6,186 shares in the last quarter. Finally, Rangeley Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics during the 2nd quarter valued at about $48,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.